Williamstown, MA -- (SBWIRE) -- 02/09/2012 -- GBI Research, the leading business intelligence provider has released its latest research "Seasonal Influenza Vaccine Market in Asia-Pacific Region - Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity Description" which essentially provides insights into the seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2017. The report also delves deep into vaccination patterns for seasonal influenza in the Asia-Pacific Region. Further, the geographical distribution of seasonal influenza vaccines across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong, Malaysia, India and Singapore are also provided in the report. The report offers a clear view of the regulatory landscape in the Asia-Pacific countries. The report also reveals the seasonal influenza vaccine R&D pipeline and offers profiles of promising vaccines. The report explores the competitive landscape including profiles for top companies. Finally, the key trend analysis on mergers and acquisitions, and licensing agreements involving seasonal influenza vaccines is also presented.

View Full Report Details and Table of Contents

Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies. In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. The patient population is of the opinion that preventive healthcare is better compared to curative healthcare; this led to increased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Major drivers in the market is increasing awareness, increasing vaccination coverage in the APAC countries and rising government support for immunization against seasonal influenza. Major restraints of the market are variable demand and limited production capacity. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.

Companies Mentioned in this Report: Sanofi Pasteur, GlaxoSmithKline Biologicals, Abbott Laboratories (Solvay Pharmaceuticals), CSL Biotherapies, Novartis Vaccines, Crucell N.V. (Berna Biotech)

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
- Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing
- Advances in Vaccine Technology and Delivery
- Adult and Adolescent Vaccines Market to 2017
- Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010
- Opportunity Analysis of H1N1 (Swine Flu) Vaccination Market
- Sanofi-Aventis (SANN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- The Global Influenza Market